0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Peptide CDMO Market Research Report 2025
Published Date: March 2025
|
Report Code: QYRE-Auto-26H6267
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Peptide CDMO Market Insights Forecast to 2028
BUY CHAPTERS

Global Peptide CDMO Market Research Report 2025

Code: QYRE-Auto-26H6267
Report
March 2025
Pages:86
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Peptide CDMO Market Size

The global market for Peptide CDMO was valued at US$ 4235 million in the year 2024 and is projected to reach a revised size of US$ 11080 million by 2031, growing at a CAGR of 15.0% during the forecast period.

Peptide CDMO Market

Peptide CDMO Market

Peptides are synthesized by coupling the carboxyl group of one amino acid to the amino group of another amino acid molecule. Due to the possibility of unintended reactions, protecting groups are common necessary. Chemical peptide synthesis most commonly starts at the carboxyl end of the peptide, and thus progress toward the amino-terminus. This is the opposite direction of protein biosynthesis.
A contract development and manufacturing company (CDMO) is a company within the pharmaceutical industry that provides drug development and manufacturing services. Pharmaceutical companies partner with CDMOs as a way to outsource drug development and drug manufacturing.
CDMO peptides production via contract peptide manufacturing is to optimize process development and achieve highly efficient conversion at every amino acid coupling to produce a high-purity crude synthetic custom peptide and minimize the demands on downstream processing.
Global key peptide CDMO producers include Bachem, PolyPeptide, CordenPharma, and others. The top five manufacturers together account for 40% of the market share, with the largest manufacturer being Bachem with 17%. At the sales level, North America is the largest sales market with a market share of over 50%, followed by Europe and China with 33% and 9% respectively. In terms of product categories, it is divided into APIs and intermediates and FDF, with the former holding the major market share of 67%. In terms of application, commercial is the top application area with a market share of 76%, followed by academic research institutions.
This report aims to provide a comprehensive presentation of the global market for Peptide CDMO, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Peptide CDMO.
The Peptide CDMO market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Peptide CDMO market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Peptide CDMO companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Peptide CDMO Market Report

Report Metric Details
Report Name Peptide CDMO Market
Accounted market size in year US$ 4235 million
Forecasted market size in 2031 US$ 11080 million
CAGR 15.0%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
  • APIs and Intermediates
  • FDF
Segment by Application
  • Commercial
  • Academic Research
  • Other
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Bachem, PolyPeptide, CordenPharma, AmbioPharm, USV Peptides, Thermofischer, Bio Basic, JPT, Genscript, Xinbang Pharma, ScinoPharm, SN Biopharm, CBL, Piramal Pharma, CPC Scientific
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Peptide CDMO company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Peptide CDMO Market growing?

Ans: The Peptide CDMO Market witnessing a CAGR of 15.0% during the forecast period 2025-2031.

What is the Peptide CDMO Market size in 2031?

Ans: The Peptide CDMO Market size in 2031 will be US$ 11080 million.

What is the market share of major companies in Peptide CDMO Market?

Ans: The top five manufacturers together account for 40% of the market share, with the largest manufacturer being Bachem with 17%.

What is the Peptide CDMO Market share by region?

Ans: At the sales level, North America is the largest sales market with a market share of over 50%, followed by Europe and China with 33% and 9% respectively.

Who are the main players in the Peptide CDMO Market report?

Ans: The main players in the Peptide CDMO Market are Bachem, PolyPeptide, CordenPharma, AmbioPharm, USV Peptides, Thermofischer, Bio Basic, JPT, Genscript, Xinbang Pharma, ScinoPharm, SN Biopharm, CBL, Piramal Pharma, CPC Scientific

What are the Application segmentation covered in the Peptide CDMO Market report?

Ans: The Applications covered in the Peptide CDMO Market report are Commercial, Academic Research, Other

What are the Type segmentation covered in the Peptide CDMO Market report?

Ans: The Types covered in the Peptide CDMO Market report are APIs and Intermediates, FDF

Recommended Reports

CDMO Services

Therapeutic CDMO

Molecule CDMO

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Peptide CDMO Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 APIs and Intermediates
1.2.3 FDF
1.3 Market by Application
1.3.1 Global Peptide CDMO Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Commercial
1.3.3 Academic Research
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Peptide CDMO Market Perspective (2020-2031)
2.2 Global Peptide CDMO Growth Trends by Region
2.2.1 Global Peptide CDMO Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Peptide CDMO Historic Market Size by Region (2020-2025)
2.2.3 Peptide CDMO Forecasted Market Size by Region (2026-2031)
2.3 Peptide CDMO Market Dynamics
2.3.1 Peptide CDMO Industry Trends
2.3.2 Peptide CDMO Market Drivers
2.3.3 Peptide CDMO Market Challenges
2.3.4 Peptide CDMO Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Peptide CDMO Players by Revenue
3.1.1 Global Top Peptide CDMO Players by Revenue (2020-2025)
3.1.2 Global Peptide CDMO Revenue Market Share by Players (2020-2025)
3.2 Global Peptide CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Peptide CDMO Revenue
3.4 Global Peptide CDMO Market Concentration Ratio
3.4.1 Global Peptide CDMO Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Peptide CDMO Revenue in 2024
3.5 Global Key Players of Peptide CDMO Head office and Area Served
3.6 Global Key Players of Peptide CDMO, Product and Application
3.7 Global Key Players of Peptide CDMO, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Peptide CDMO Breakdown Data by Type
4.1 Global Peptide CDMO Historic Market Size by Type (2020-2025)
4.2 Global Peptide CDMO Forecasted Market Size by Type (2026-2031)
5 Peptide CDMO Breakdown Data by Application
5.1 Global Peptide CDMO Historic Market Size by Application (2020-2025)
5.2 Global Peptide CDMO Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Peptide CDMO Market Size (2020-2031)
6.2 North America Peptide CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Peptide CDMO Market Size by Country (2020-2025)
6.4 North America Peptide CDMO Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Peptide CDMO Market Size (2020-2031)
7.2 Europe Peptide CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Peptide CDMO Market Size by Country (2020-2025)
7.4 Europe Peptide CDMO Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Peptide CDMO Market Size (2020-2031)
8.2 Asia-Pacific Peptide CDMO Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Peptide CDMO Market Size by Region (2020-2025)
8.4 Asia-Pacific Peptide CDMO Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Peptide CDMO Market Size (2020-2031)
9.2 Latin America Peptide CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Peptide CDMO Market Size by Country (2020-2025)
9.4 Latin America Peptide CDMO Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Peptide CDMO Market Size (2020-2031)
10.2 Middle East & Africa Peptide CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Peptide CDMO Market Size by Country (2020-2025)
10.4 Middle East & Africa Peptide CDMO Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Bachem
11.1.1 Bachem Company Details
11.1.2 Bachem Business Overview
11.1.3 Bachem Peptide CDMO Introduction
11.1.4 Bachem Revenue in Peptide CDMO Business (2020-2025)
11.1.5 Bachem Recent Development
11.2 PolyPeptide
11.2.1 PolyPeptide Company Details
11.2.2 PolyPeptide Business Overview
11.2.3 PolyPeptide Peptide CDMO Introduction
11.2.4 PolyPeptide Revenue in Peptide CDMO Business (2020-2025)
11.2.5 PolyPeptide Recent Development
11.3 CordenPharma
11.3.1 CordenPharma Company Details
11.3.2 CordenPharma Business Overview
11.3.3 CordenPharma Peptide CDMO Introduction
11.3.4 CordenPharma Revenue in Peptide CDMO Business (2020-2025)
11.3.5 CordenPharma Recent Development
11.4 AmbioPharm
11.4.1 AmbioPharm Company Details
11.4.2 AmbioPharm Business Overview
11.4.3 AmbioPharm Peptide CDMO Introduction
11.4.4 AmbioPharm Revenue in Peptide CDMO Business (2020-2025)
11.4.5 AmbioPharm Recent Development
11.5 USV Peptides
11.5.1 USV Peptides Company Details
11.5.2 USV Peptides Business Overview
11.5.3 USV Peptides Peptide CDMO Introduction
11.5.4 USV Peptides Revenue in Peptide CDMO Business (2020-2025)
11.5.5 USV Peptides Recent Development
11.6 Thermofischer
11.6.1 Thermofischer Company Details
11.6.2 Thermofischer Business Overview
11.6.3 Thermofischer Peptide CDMO Introduction
11.6.4 Thermofischer Revenue in Peptide CDMO Business (2020-2025)
11.6.5 Thermofischer Recent Development
11.7 Bio Basic
11.7.1 Bio Basic Company Details
11.7.2 Bio Basic Business Overview
11.7.3 Bio Basic Peptide CDMO Introduction
11.7.4 Bio Basic Revenue in Peptide CDMO Business (2020-2025)
11.7.5 Bio Basic Recent Development
11.8 JPT
11.8.1 JPT Company Details
11.8.2 JPT Business Overview
11.8.3 JPT Peptide CDMO Introduction
11.8.4 JPT Revenue in Peptide CDMO Business (2020-2025)
11.8.5 JPT Recent Development
11.9 Genscript
11.9.1 Genscript Company Details
11.9.2 Genscript Business Overview
11.9.3 Genscript Peptide CDMO Introduction
11.9.4 Genscript Revenue in Peptide CDMO Business (2020-2025)
11.9.5 Genscript Recent Development
11.10 Xinbang Pharma
11.10.1 Xinbang Pharma Company Details
11.10.2 Xinbang Pharma Business Overview
11.10.3 Xinbang Pharma Peptide CDMO Introduction
11.10.4 Xinbang Pharma Revenue in Peptide CDMO Business (2020-2025)
11.10.5 Xinbang Pharma Recent Development
11.11 ScinoPharm
11.11.1 ScinoPharm Company Details
11.11.2 ScinoPharm Business Overview
11.11.3 ScinoPharm Peptide CDMO Introduction
11.11.4 ScinoPharm Revenue in Peptide CDMO Business (2020-2025)
11.11.5 ScinoPharm Recent Development
11.12 SN Biopharm
11.12.1 SN Biopharm Company Details
11.12.2 SN Biopharm Business Overview
11.12.3 SN Biopharm Peptide CDMO Introduction
11.12.4 SN Biopharm Revenue in Peptide CDMO Business (2020-2025)
11.12.5 SN Biopharm Recent Development
11.13 CBL
11.13.1 CBL Company Details
11.13.2 CBL Business Overview
11.13.3 CBL Peptide CDMO Introduction
11.13.4 CBL Revenue in Peptide CDMO Business (2020-2025)
11.13.5 CBL Recent Development
11.14 Piramal Pharma
11.14.1 Piramal Pharma Company Details
11.14.2 Piramal Pharma Business Overview
11.14.3 Piramal Pharma Peptide CDMO Introduction
11.14.4 Piramal Pharma Revenue in Peptide CDMO Business (2020-2025)
11.14.5 Piramal Pharma Recent Development
11.15 CPC Scientific
11.15.1 CPC Scientific Company Details
11.15.2 CPC Scientific Business Overview
11.15.3 CPC Scientific Peptide CDMO Introduction
11.15.4 CPC Scientific Revenue in Peptide CDMO Business (2020-2025)
11.15.5 CPC Scientific Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
 Table 1. Global Peptide CDMO Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Key Players of APIs and Intermediates
 Table 3. Key Players of FDF
 Table 4. Global Peptide CDMO Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 5. Global Peptide CDMO Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 6. Global Peptide CDMO Market Size by Region (2020-2025) & (US$ Million)
 Table 7. Global Peptide CDMO Market Share by Region (2020-2025)
 Table 8. Global Peptide CDMO Forecasted Market Size by Region (2026-2031) & (US$ Million)
 Table 9. Global Peptide CDMO Market Share by Region (2026-2031)
 Table 10. Peptide CDMO Market Trends
 Table 11. Peptide CDMO Market Drivers
 Table 12. Peptide CDMO Market Challenges
 Table 13. Peptide CDMO Market Restraints
 Table 14. Global Peptide CDMO Revenue by Players (2020-2025) & (US$ Million)
 Table 15. Global Peptide CDMO Market Share by Players (2020-2025)
 Table 16. Global Top Peptide CDMO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Peptide CDMO as of 2024)
 Table 17. Ranking of Global Top Peptide CDMO Companies by Revenue (US$ Million) in 2024
 Table 18. Global 5 Largest Players Market Share by Peptide CDMO Revenue (CR5 and HHI) & (2020-2025)
 Table 19. Global Key Players of Peptide CDMO, Headquarters and Area Served
 Table 20. Global Key Players of Peptide CDMO, Product and Application
 Table 21. Global Key Players of Peptide CDMO, Date of Enter into This Industry
 Table 22. Mergers & Acquisitions, Expansion Plans
 Table 23. Global Peptide CDMO Market Size by Type (2020-2025) & (US$ Million)
 Table 24. Global Peptide CDMO Revenue Market Share by Type (2020-2025)
 Table 25. Global Peptide CDMO Forecasted Market Size by Type (2026-2031) & (US$ Million)
 Table 26. Global Peptide CDMO Revenue Market Share by Type (2026-2031)
 Table 27. Global Peptide CDMO Market Size by Application (2020-2025) & (US$ Million)
 Table 28. Global Peptide CDMO Revenue Market Share by Application (2020-2025)
 Table 29. Global Peptide CDMO Forecasted Market Size by Application (2026-2031) & (US$ Million)
 Table 30. Global Peptide CDMO Revenue Market Share by Application (2026-2031)
 Table 31. North America Peptide CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 32. North America Peptide CDMO Market Size by Country (2020-2025) & (US$ Million)
 Table 33. North America Peptide CDMO Market Size by Country (2026-2031) & (US$ Million)
 Table 34. Europe Peptide CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 35. Europe Peptide CDMO Market Size by Country (2020-2025) & (US$ Million)
 Table 36. Europe Peptide CDMO Market Size by Country (2026-2031) & (US$ Million)
 Table 37. Asia-Pacific Peptide CDMO Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 38. Asia-Pacific Peptide CDMO Market Size by Region (2020-2025) & (US$ Million)
 Table 39. Asia-Pacific Peptide CDMO Market Size by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Peptide CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 41. Latin America Peptide CDMO Market Size by Country (2020-2025) & (US$ Million)
 Table 42. Latin America Peptide CDMO Market Size by Country (2026-2031) & (US$ Million)
 Table 43. Middle East & Africa Peptide CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 44. Middle East & Africa Peptide CDMO Market Size by Country (2020-2025) & (US$ Million)
 Table 45. Middle East & Africa Peptide CDMO Market Size by Country (2026-2031) & (US$ Million)
 Table 46. Bachem Company Details
 Table 47. Bachem Business Overview
 Table 48. Bachem Peptide CDMO Product
 Table 49. Bachem Revenue in Peptide CDMO Business (2020-2025) & (US$ Million)
 Table 50. Bachem Recent Development
 Table 51. PolyPeptide Company Details
 Table 52. PolyPeptide Business Overview
 Table 53. PolyPeptide Peptide CDMO Product
 Table 54. PolyPeptide Revenue in Peptide CDMO Business (2020-2025) & (US$ Million)
 Table 55. PolyPeptide Recent Development
 Table 56. CordenPharma Company Details
 Table 57. CordenPharma Business Overview
 Table 58. CordenPharma Peptide CDMO Product
 Table 59. CordenPharma Revenue in Peptide CDMO Business (2020-2025) & (US$ Million)
 Table 60. CordenPharma Recent Development
 Table 61. AmbioPharm Company Details
 Table 62. AmbioPharm Business Overview
 Table 63. AmbioPharm Peptide CDMO Product
 Table 64. AmbioPharm Revenue in Peptide CDMO Business (2020-2025) & (US$ Million)
 Table 65. AmbioPharm Recent Development
 Table 66. USV Peptides Company Details
 Table 67. USV Peptides Business Overview
 Table 68. USV Peptides Peptide CDMO Product
 Table 69. USV Peptides Revenue in Peptide CDMO Business (2020-2025) & (US$ Million)
 Table 70. USV Peptides Recent Development
 Table 71. Thermofischer Company Details
 Table 72. Thermofischer Business Overview
 Table 73. Thermofischer Peptide CDMO Product
 Table 74. Thermofischer Revenue in Peptide CDMO Business (2020-2025) & (US$ Million)
 Table 75. Thermofischer Recent Development
 Table 76. Bio Basic Company Details
 Table 77. Bio Basic Business Overview
 Table 78. Bio Basic Peptide CDMO Product
 Table 79. Bio Basic Revenue in Peptide CDMO Business (2020-2025) & (US$ Million)
 Table 80. Bio Basic Recent Development
 Table 81. JPT Company Details
 Table 82. JPT Business Overview
 Table 83. JPT Peptide CDMO Product
 Table 84. JPT Revenue in Peptide CDMO Business (2020-2025) & (US$ Million)
 Table 85. JPT Recent Development
 Table 86. Genscript Company Details
 Table 87. Genscript Business Overview
 Table 88. Genscript Peptide CDMO Product
 Table 89. Genscript Revenue in Peptide CDMO Business (2020-2025) & (US$ Million)
 Table 90. Genscript Recent Development
 Table 91. Xinbang Pharma Company Details
 Table 92. Xinbang Pharma Business Overview
 Table 93. Xinbang Pharma Peptide CDMO Product
 Table 94. Xinbang Pharma Revenue in Peptide CDMO Business (2020-2025) & (US$ Million)
 Table 95. Xinbang Pharma Recent Development
 Table 96. ScinoPharm Company Details
 Table 97. ScinoPharm Business Overview
 Table 98. ScinoPharm Peptide CDMO Product
 Table 99. ScinoPharm Revenue in Peptide CDMO Business (2020-2025) & (US$ Million)
 Table 100. ScinoPharm Recent Development
 Table 101. SN Biopharm Company Details
 Table 102. SN Biopharm Business Overview
 Table 103. SN Biopharm Peptide CDMO Product
 Table 104. SN Biopharm Revenue in Peptide CDMO Business (2020-2025) & (US$ Million)
 Table 105. SN Biopharm Recent Development
 Table 106. CBL Company Details
 Table 107. CBL Business Overview
 Table 108. CBL Peptide CDMO Product
 Table 109. CBL Revenue in Peptide CDMO Business (2020-2025) & (US$ Million)
 Table 110. CBL Recent Development
 Table 111. Piramal Pharma Company Details
 Table 112. Piramal Pharma Business Overview
 Table 113. Piramal Pharma Peptide CDMO Product
 Table 114. Piramal Pharma Revenue in Peptide CDMO Business (2020-2025) & (US$ Million)
 Table 115. Piramal Pharma Recent Development
 Table 116. CPC Scientific Company Details
 Table 117. CPC Scientific Business Overview
 Table 118. CPC Scientific Peptide CDMO Product
 Table 119. CPC Scientific Revenue in Peptide CDMO Business (2020-2025) & (US$ Million)
 Table 120. CPC Scientific Recent Development
 Table 121. Research Programs/Design for This Report
 Table 122. Key Data Information from Secondary Sources
 Table 123. Key Data Information from Primary Sources
 Table 124. Authors List of This Report


List of Figures
 Figure 1. Peptide CDMO Picture
 Figure 2. Global Peptide CDMO Market Size Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Peptide CDMO Market Share by Type: 2024 VS 2031
 Figure 4. APIs and Intermediates Features
 Figure 5. FDF Features
 Figure 6. Global Peptide CDMO Market Size by Application (2020-2031) & (US$ Million)
 Figure 7. Global Peptide CDMO Market Share by Application: 2024 VS 2031
 Figure 8. Commercial Case Studies
 Figure 9. Academic Research Case Studies
 Figure 10. Other Case Studies
 Figure 11. Peptide CDMO Report Years Considered
 Figure 12. Global Peptide CDMO Market Size (US$ Million), Year-over-Year: 2020-2031
 Figure 13. Global Peptide CDMO Market Size, (US$ Million), 2020 VS 2024 VS 2031
 Figure 14. Global Peptide CDMO Market Share by Region: 2024 VS 2031
 Figure 15. Global Peptide CDMO Market Share by Players in 2024
 Figure 16. Global Top Peptide CDMO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Peptide CDMO as of 2024)
 Figure 17. The Top 10 and 5 Players Market Share by Peptide CDMO Revenue in 2024
 Figure 18. North America Peptide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 19. North America Peptide CDMO Market Share by Country (2020-2031)
 Figure 20. United States Peptide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 21. Canada Peptide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 22. Europe Peptide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 23. Europe Peptide CDMO Market Share by Country (2020-2031)
 Figure 24. Germany Peptide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 25. France Peptide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 26. U.K. Peptide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 27. Italy Peptide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 28. Russia Peptide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 29. Nordic Countries Peptide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 30. Asia-Pacific Peptide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 31. Asia-Pacific Peptide CDMO Market Share by Region (2020-2031)
 Figure 32. China Peptide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 33. Japan Peptide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 34. South Korea Peptide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 35. Southeast Asia Peptide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 36. India Peptide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 37. Australia Peptide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 38. Latin America Peptide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 39. Latin America Peptide CDMO Market Share by Country (2020-2031)
 Figure 40. Mexico Peptide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 41. Brazil Peptide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 42. Middle East & Africa Peptide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 43. Middle East & Africa Peptide CDMO Market Share by Country (2020-2031)
 Figure 44. Turkey Peptide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 45. Saudi Arabia Peptide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 46. UAE Peptide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 47. Bachem Revenue Growth Rate in Peptide CDMO Business (2020-2025)
 Figure 48. PolyPeptide Revenue Growth Rate in Peptide CDMO Business (2020-2025)
 Figure 49. CordenPharma Revenue Growth Rate in Peptide CDMO Business (2020-2025)
 Figure 50. AmbioPharm Revenue Growth Rate in Peptide CDMO Business (2020-2025)
 Figure 51. USV Peptides Revenue Growth Rate in Peptide CDMO Business (2020-2025)
 Figure 52. Thermofischer Revenue Growth Rate in Peptide CDMO Business (2020-2025)
 Figure 53. Bio Basic Revenue Growth Rate in Peptide CDMO Business (2020-2025)
 Figure 54. JPT Revenue Growth Rate in Peptide CDMO Business (2020-2025)
 Figure 55. Genscript Revenue Growth Rate in Peptide CDMO Business (2020-2025)
 Figure 56. Xinbang Pharma Revenue Growth Rate in Peptide CDMO Business (2020-2025)
 Figure 57. ScinoPharm Revenue Growth Rate in Peptide CDMO Business (2020-2025)
 Figure 58. SN Biopharm Revenue Growth Rate in Peptide CDMO Business (2020-2025)
 Figure 59. CBL Revenue Growth Rate in Peptide CDMO Business (2020-2025)
 Figure 60. Piramal Pharma Revenue Growth Rate in Peptide CDMO Business (2020-2025)
 Figure 61. CPC Scientific Revenue Growth Rate in Peptide CDMO Business (2020-2025)
 Figure 62. Bottom-up and Top-down Approaches for This Report
 Figure 63. Data Triangulation
 Figure 64. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Novocure